At Axela, we create tools and content to simplify multiplex biomarker detection for translational research and diagnostic testing. Our systems are built upon advanced flow-through technologies that enable rapid, real time multiplex immunoassays as well as high performance nucleic acid and protein microarray analysis. We provide easy to use, automated platforms with the flexibility of generating custom assays that can accelerate the transition of biomarker discoveries from the research laboratory to the clinic. These platforms are especially designed for partners focused on developing near patient tests in the areas of oncology, immunology, or for specialty applications such as traumatic brain injury.
About Us
Latest News
- February 1, 2013 – Axela Inc. Retains Investment Bank to Evaluate Strategic Opportunities
- January 24, 2013 – Axela Inc. Announces Cardiac Troponin Biomarker Complex Detection Patent Issued
- August 21, 2012 – Axela Inc. and OvaGene Oncology Inc. Announce Molecular Diagnostics Partnership for Therapy Selection in Ovarian Cancer
[more]
Events
- October 7 - 9, 2012
BioPartnering Future Europe
Brussels, Belgium - November 14 - 17, 2012
MEDICA 2012 (Hall 3, Stand 3H14)
Dusseldorf, Germany
[more]
Latest Literature
- Identification of Spurious Signal in Immunoassays Due to Serum Antibodies Against Blocking Proteins [PDF]
[more]




